Noesis Capital Mangement Corp Acquires 275 Shares of Stryker Co. (NYSE:SYK)

Noesis Capital Mangement Corp grew its position in shares of Stryker Co. (NYSE:SYK) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,148 shares of the medical technology company’s stock after purchasing an additional 275 shares during the period. Stryker makes up about 4.3% of Noesis Capital Mangement Corp’s holdings, making the stock its 4th largest holding. Noesis Capital Mangement Corp’s holdings in Stryker were worth $18,312,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA lifted its stake in Stryker by 203.3% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Rogco LP acquired a new position in Stryker during the fourth quarter worth $30,000. HBC Financial Services PLLC acquired a new position in Stryker during the fourth quarter worth $37,000. Bourgeon Capital Management LLC acquired a new position in Stryker during the fourth quarter worth $37,000. Finally, Venturi Wealth Management LLC lifted its stake in Stryker by 97.1% during the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after purchasing an additional 67 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock traded up $1.82 during mid-day trading on Friday, hitting $328.45. 1,589,424 shares of the stock were exchanged, compared to its average volume of 1,415,127. The stock’s fifty day simple moving average is $346.99 and its two-hundred day simple moving average is $317.29. The stock has a market capitalization of $125.12 billion, a price-to-earnings ratio of 37.49, a P/E/G ratio of 2.55 and a beta of 0.91. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.97 and a current ratio of 1.71.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the company posted $2.14 earnings per share. On average, analysts forecast that Stryker Co. will post 11.94 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.97%. Stryker’s dividend payout ratio (DPR) is 36.53%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SYK. TD Cowen increased their price objective on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Evercore ISI increased their price objective on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Truist Financial increased their price objective on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research note on Wednesday, January 31st. Royal Bank of Canada increased their price objective on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Finally, Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective on the stock in a research note on Wednesday, January 31st. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $365.94.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.